Homoarginine and blood pressure: a 10-year prospective relationship in normotensives.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
27
05
2020
accepted:
08
11
2020
revised:
23
10
2020
pubmed:
28
5
2021
medline:
11
3
2022
entrez:
27
5
2021
Statut:
ppublish
Résumé
Nitric oxide plays a major role in the regulation of blood pressure, and impaired nitric oxide bioavailability contributes to the development of hypertension (HT). Various factors may contribute to nitric oxide bioavailability-including availability of the substrate for nitric oxide synthesis, L-arginine and its homolog L-homoarginine. We investigated whether blood pressure after 10 years associates with baseline L-homoarginine in participants who remained normotensive (NT) or developed HT, respectively. Data from the South African leg of the Prospective Urban and Rural Epidemiology study, performed in the North-West Province, were used. We investigated participants who either remained NT (N = 166) or who developed HT (N = 166) over 10 years. Blood pressure was measured with validated OMRON devices and serum L-homoarginine was analyzed with liquid chromatography-tandem mass spectrometry. L-homoarginine levels were similar at baseline (p = 0.39) and follow-up (p = 0.93) between NT and hypertensive groups. In the group that remained NT after 10 years, baseline L-homoarginine correlated positively with follow-up brachial systolic blood pressure (adj.R
Identifiants
pubmed: 34040153
doi: 10.1038/s41371-020-00449-5
pii: 10.1038/s41371-020-00449-5
doi:
Substances chimiques
Homoarginine
156-86-5
Nitric Oxide
31C4KY9ESH
Arginine
94ZLA3W45F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-143Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65:291–8.
doi: 10.1161/HYPERTENSIONAHA.114.04394
Kengne AP, Ntyintyane LM, Mayosi BM. A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr. 2012;23:103.
doi: 10.5830/CVJA-2011-042
Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension. 1995;25:1202–11.
doi: 10.1161/01.HYP.25.6.1202
Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455–9.
doi: 10.1161/01.ATV.0000081742.92006.59
Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang W-Z, et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004;110:3680–6.
doi: 10.1161/01.CIR.0000149748.79945.52
Böger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005;10:S19–25.
doi: 10.1177/1358836X0501000104
Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17:1128–34.
doi: 10.1681/ASN.2005101119
Valtonen P, Laitinen T, Lyyra-Laitinen T, Raitakari OT, Juonala M, Viikari JS, et al. Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. Circ J. 2008;72:1879–84.
doi: 10.1253/circj.CJ-08-0240
Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: detailed comparison of l-arginine, homo-l-arginine, their N ω-hydroxy derivatives, and N ω-hydroxynor-l-arginine. Biochemistry. 1998;37:10453–60.
doi: 10.1021/bi980742t
Kakoki M, Kim HS, Edgell CJS, Maeda N, Smithies O, Mattson DL. Amino acids as modulators of endothelium-derived nitric oxide. Am J Physiol Ren Physiol. 2006;291:F297–304.
doi: 10.1152/ajprenal.00417.2005
Hrabak A, Bajor T, Temesi A. Comparison of substrate and inhibitor specificity of arginase and nitric oxide (NO) synthase for arginine analogs and related compounds in murine and rat macrophages. Biochem Biophys Res Commun. 1994;198:206–12.
doi: 10.1006/bbrc.1994.1029
Reczkowski RS, Ash DE. Rat liver arginase: kinetic mechanism, alternate substrates, and inhibitors. Arch Biochem Biophys. 1994;312:31–7.
doi: 10.1006/abbi.1994.1276
Tommasi S, Elliot DJ, Da Boit M, Gray SR, Lewis BC, Mangoni AA. Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance. Sci Rep. 2018;8:1–13.
van der Zwan LP, Davids M, Scheffer PG, Dekker JM, Stehouwer CD, Teerlink T. L-homoarginine and L-arginine are antagonistically related to blood pressure in an elderly population: the Hoorn study. J Hypertens. 2013;31:1114–23.
doi: 10.1097/HJH.0b013e32836037fb
Pilz S, Teerlink T, Scheffer PG, Meinitzer A, Rutters F, Tomaschitz A, et al. Homoarginine and mortality in an older population: the Hoorn study. Eur J Clin Investig. 2014;44:200–8.
doi: 10.1111/eci.12208
Kayacelebi AA, Nguyen TH, Neil C, Horowitz JD, Jordan J, Tsikas D. Homoarginine and 3-nitrotyrosine in patients with takotsubo cardiomyopathy. Int J Cardiol. 2014;173:546–7.
doi: 10.1016/j.ijcard.2014.03.080
Seedat Y, Rayner B, Veriava Y. South African hypertension practice guideline 2014. Cardiovasc J Afr. 2014;25:288.
doi: 10.5830/CVJA-2014-062
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013;22:193–278.
doi: 10.3109/08037051.2013.812549
Marfell-Jones MJ, Stewart AD, de Ridder JH. International standardsfor anthropometric assessment. Lower Hutt, New Zealand. 2012.
Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E. Stable isotope dilution assay for liquid chromatography–tandem mass spectrometric determination of l-homoarginine in human plasma. J Chromatogr B. 2011;879:2294–8.
doi: 10.1016/j.jchromb.2011.06.016
Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B. 2007;851:211–9.
doi: 10.1016/j.jchromb.2006.11.052
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
doi: 10.1093/clinchem/18.6.499
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.
doi: 10.1056/NEJMoa1114248
Stuehr DJ. Enzymes of the L-arginine to nitric oxide pathway. J Nutr. 2004;134:2748S–51S.
doi: 10.1093/jn/134.10.2748S
El‐Bassossy HM, El‐Fawal R, Fahmy A, Watson ML. Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol. 2013;169:693–703.
doi: 10.1111/bph.12144